ATRC
AtriCure, Inc.
ATRC's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ATRC overall, supported by stronger valuation and stronger modeled upside.
ATRC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
ATRC's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ATRC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 37x | $11.06 | -80% |
| Fair | 61x | $18.23 | -67% |
| Current | 187x | $55.98 | — |
| Expensive | 203x | $60.96 | +8.9% |
| Forward | 211x | $55.98 | — |
Historical ranges are pointers, not guarantees.
ATRC's PE is in its expensive range at 187x. On analysts' estimates for next year's earnings, today's price would be 211x.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over ATRC in the historical PE scenario, which offers more potential upside but is not a forecast.
ATRC Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect ATRC to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ATRC on the outlook, with more favorable valuation expectations.
ATRC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.26 | -12% |
| Q3 2026 | $0.30 | +$0.91 |
| Q2 2026 | $0.21 | +$0.98 |
| Q1 2026 | -$0.10 | +$0.71 |
| Q4 2025 | -$0.24 | +$0.71 |
| Q3 2025 | -$0.61 | +$0.22 |
| Q2 2025 | -$0.77 | +$0.09 |
| Q1 2025 | -$0.81 | -$0.01 |
| Q4 2024 | -$0.95 | -$0.29 |
ATRC has returned to profit: it earned $0.30 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ATRC on earnings, with more consistent year-over-year improvement.
ATRC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $154.5M | +15% |
| Q2 2026 | $153.6M | +13% |
| Q1 2026 | $141.2M | +14% |
| Q4 2025 | $140.5M | +13% |
| Q3 2025 | $134.3M | +16% |
| Q2 2025 | $136.1M | +17% |
| Q1 2025 | $123.6M | +14% |
| Q4 2024 | $124.3M | +17% |
ATRC's revenue has grown year over year for 23 quarters in a row: $154M last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.8% | +2.7 points |
| Q2 2026 | 6.3% | +11 points |
| Q1 2026 | 0.4% | +5.2 points |
| Q4 2025 | 1.8% | +14 points |
| Q3 2025 | 0.1% | +6.5 points |
| Q2 2025 | -4.5% | +1.6 points |
| Q1 2025 | -4.8% | +5.2 points |
| Q4 2024 | -12% | -3.5 points |
ATRC's operating margin was 2.8% last quarter, up 2.7 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ATRC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ATRC on profitability, with a higher operating margin.
ATRC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $23.9M | -0.7% |
| Q2 2026 | $18.4M | -2.8% |
| Q1 2026 | -$7.8M | +$5.4M |
| Q4 2025 | $18.4M | +486% |
| Q3 2025 | $24.1M | +47% |
| Q2 2025 | $19M | +279% |
| Q1 2025 | -$13.2M | +$10.6M |
| Q4 2024 | $3.1M | +153% |
ATRC generated $53M in free cash flow over the past year, up 60% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ATRC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +963K shares |
| 1 year | +4% | +1.9M shares |
| 3 years | +7.4% | +3.4M shares |
| 5 years | +8.1% | +3.7M shares |
| Available history | +33% | +12.2M shares |
ATRC has 50M diluted shares, up 4% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ATRC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ATRC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -3.3x | Net Cash |
| Q2 2026 | -3.2x | Net Cash |
| Q1 2026 | -4.8x | Net Cash |
| Q4 2025 | -9.5x | Net Cash |
| Q2 2022 | 0.1x | Very low |
| Q1 2022 | 0.5x | Very low |
| Q4 2021 | 0.3x | Very low |
| Q3 2021 | 0.3x | Very low |
ATRC has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ATRC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.5 | Neutral |
| Stochastic | 75.6 | Neutral |
ATRC's weekly RSI is 67 (neutral) and its Stochastic is 76 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ATRC PE vs Healthcare Sector
| Metric | ATRC | Sector median | Relative |
|---|---|---|---|
| PE | 187x | 26x | 622% above |
| PE % | 79 | 29 | 50 pts above |
ATRC is trading at 187x earnings, a 622% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over ATRC on valuation relative to its sector.
ATRC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $57.5 | 2.7% below |
| 20 week MA | $49.1 | 14% above |
| 50 week MA | $39.3 | 43% above |
| 100 week MA | $36.8 | 52% above |
| 200 week MA | $36.3 | 54% above |
ATRC's trend is up, with a small recent dip: it's below only its 8-week average, and 54% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ATRC on trend strength, trading above more of its moving averages.
ATRC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.0 | $57.6 | +80% |
| 2021 | $57.6 | $73.4 | +27% |
| 2022 | $73.4 | $43.7 | -40% |
| 2023 | $43.7 | $35.7 | -18% |
| 2024 | $35.7 | $30.7 | -14% |
| 2025 | $30.7 | $40.3 | +32% |
| 2026 YTD | $40.3 | $56.0 | +39% |
ATRC has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.